Clinical Trials Browser

Has results × Breast Neoplasms × Paclitaxel × Clear all

NCT02689427 2026-05-12

Enzalutamide and Paclitaxel Before Surgery in Treating Patients With Stage I-III Androgen Receptor-Positive Triple-Negative Breast Cancer

Phase 2 Completed

24 enrolled 7 charts

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT02734290 2026-04-24

Standard of Care Chemotherapy Plus Pembrolizumab for Breast Cancer

Phase 1/2 Active not recruiting

29 enrolled 12 charts

Breast Neoplasms, Neoplasm Metastasis, Triple Negative Breast Neoplasms

NCT03742102 2026-04-24

BEGONIA

Phase 1/2 Active not recruiting

243 enrolled 13 charts

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT02957968 2026-04-21

Neoadjuvant Pembrolizumab + Decitabine Followed by Std Neoadj Chemo for Locally Advanced HER2- Breast Ca

Phase 2 Active not recruiting

46 enrolled 21 charts

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT02883062 2026-04-13

Carboplatin and Paclitaxel With or Without Atezolizumab Before Surgery in Treating Patients With Newly Diagnosed, Stage II-III Triple-Negative Breast Cancer

Phase 2 Active not recruiting

67 enrolled 16 charts

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT03568422 2026-03-27

CFI-402257 in Combination With Paclitaxel in Patients With Advanced/Metastatic HER2-Negative Breast Cancer

Phase 1/2 Active not recruiting

37 enrolled 14 charts

Breast Neoplasms

NCT02654119 2026-03-23

Cyclophosphamide, Paclitaxel, and Trastuzumab in Treating Stage I-II HER2/Neu Positive Breast Cancer After Surgery

Phase 2 Completed

20 enrolled 12 charts

Breast Neoplasms

NCT04293393 2026-03-12

CARABELA

Phase 2 Active not recruiting

200 enrolled 27 charts

Breast Neoplasms

NCT02779855 2026-03-10

Talimogene Laherparepvec in Combination With Neoadjuvant Chemotherapy in Triple Negative Breast Cancer

Phase 1/2 Completed

50 enrolled 12 charts

Breast Neoplasms, Carcinoma, Ductal, Breast, Carcinoma, Ductal, Triple Negative Breast Neoplasms

NCT04494425 2026-03-04

DB-06

Phase 3 Active not recruiting

866 enrolled 25 charts 1 FDA

Breast Neoplasms

NCT00003042 2026-02-20

Chemotherapy and Stem Cell Transplantation in Treating Patients With Stage IIIB Breast Cancer

Phase 2 Completed

41 enrolled 9 charts

Breast Neoplasms, Inflammatory Breast Neoplasms

NCT01853748 2026-02-19

T-DM1 vs Paclitaxel/Trastuzumab for Breast (ATEMPT Trial)

Phase 2 Completed

512 enrolled 28 charts

Breast Neoplasms

NCT03301350 2026-02-13

Neoadjuvant Carbo/Paclitaxel Followed by Doxorubicin/Cyclophosphamide in Breast Cancer

Phase 2 Completed

29 enrolled 15 charts

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT03101748 2026-02-12

Neratinib and Paclitaxel With or Without Pertuzumab and Trastuzumab Before Combination Chemotherapy in Treating Patients With Metastatic or Locally Advanced Breast Cancer

Phase 1/2 Terminated

34 enrolled 15 charts

Breast Neoplasms, Inflammatory Breast Neoplasms

NCT01796197 2026-02-05

Paclitaxel + Trastuzumab + Pertuzumab as Pre-Op for Inflammatory BrCa

Phase 2 Completed

23 enrolled 10 charts

Breast Neoplasms

NCT02876302 2026-02-04

Study Of Ruxolitinib (INCB018424) With Preoperative Chemotherapy For Triple Negative Inflammatory Breast Cancer

Phase 2 Active not recruiting

23 enrolled 18 charts

Breast Neoplasms, Inflammatory Breast Neoplasms, Triple Negative Breast Neoplasms

NCT03199885 2025-12-30

Testing the Drug Atezolizumab or Placebo With Usual Therapy in First-Line HER2-Positive Metastatic Breast Cancer

Phase 3 Completed

190 enrolled 12 charts

Breast Neoplasms

NCT02688803 2025-12-04

OTT15-04

Phase 4 Terminated

2 enrolled 4 charts

Breast Neoplasms

NCT01358877 2025-11-28

APHINITY

Phase 3 Completed

4,804 enrolled 45 charts 1 FDA

Breast Neoplasms

NCT01750073 2025-11-18

Paclitaxel & Cyclophosphamide With or Without Trastuzumab Before Surgery in Treating Previously Untreated Breast Cancer

Phase 2 Active not recruiting

92 enrolled 17 charts

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT04425018 2025-11-18

MARGOT

Phase 2 Active not recruiting

174 enrolled 19 charts

Breast Neoplasms

NCT02593175 2025-11-06

Women's MoonShot: Neoadjuvant Treatment With PaCT for Patients With Locally Advanced TNBC

Phase 2 Completed

43 enrolled 8 charts

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT02711137 2025-10-21

Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies

Phase 1/2 Terminated

137 enrolled 31 charts

BreastCNSGastrointestinalGenitourinaryGynecologicLymphoidMyeloidOther hematologic neoplasmPlasma cellThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Glioblastoma, Leukemia, Lymphoma, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Colorectal Neoplasms, Lymphoma, Large B-Cell, Diffuse, Primary Myelofibrosis

NCT03734029 2025-10-06

Trastuzumab Deruxtecan (DS-8201a) Versus Investigator's Choice for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed [DESTINY-Breast04]

Phase 3 Active not recruiting

557 enrolled 22 charts 1 FDA

Breast Neoplasms, Neoplasm Metastasis

NCT00861705 2025-09-30

Paclitaxel With or Without Carboplatin and/or Bevacizumab Followed by Doxorubicin and Cyclophosphamide in Treating Patients With Breast Cancer That Can Be Removed by Surgery

Phase 2 Completed

454 enrolled 23 charts

Breast Neoplasms, Breast Neoplasms, Male, Triple Negative Breast Neoplasms

NCT00295893 2025-09-25

Combination Chemotherapy With or Without Trastuzumab in Treating Patients With Stage II or Stage III Breast Cancer

Phase 2 Active not recruiting

121 enrolled 10 charts

Breast Neoplasms, Carcinoma, Ductal, Breast, Carcinoma, Lobular, Breast Neoplasms, Male, Inflammatory Breast Neoplasms

NCT04862585 2025-08-20

Safely Stopping Pre-medications in Patients With Breast Cancer Who Are Receiving Paclitaxel

Phase 2/3 Completed

130 enrolled 8 charts

Breast Carcinoma In Situ, Breast Neoplasms

NCT00770809 2025-08-15

Paclitaxel and Trastuzumab With or Without Lapatinib in Treating Patients With Stage II or Stage III Breast Cancer That Can Be Removed by Surgery

Phase 3 Completed

305 enrolled 10 charts

Breast Neoplasms, Breast Neoplasms, Male

NCT02776917 2025-08-07

Study of Cirmtuzumab and Paclitaxel for Metastatic or Locally Advanced, Unresectable Breast Cancer

Phase 1 Completed

23 enrolled 10 charts

Breast Neoplasms

NCT00070564 2025-07-31

S0221 Adjuvant Doxorubicin, Cyclophosphamide, and Paclitaxel in Treating Patients With Breast Cancer

Phase 3 Active not recruiting

3,294 enrolled 22 charts

Breast Neoplasms, Breast Neoplasms, Male

NCT01275677 2025-07-14

Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer

Phase 3 Completed

3,270 enrolled 16 charts

Breast Neoplasms

NCT03747120 2025-06-27

Neoadjuvant Her2-targeted Therapy and Immunotherapy With Pembrolizumab [IIT2018-04-MCARTHUR-NEOHP]

Phase 2 Active not recruiting

138 enrolled 14 charts

Breast Neoplasms

NCT04251169 2025-06-03

TATEN

Phase 2 Terminated

20 enrolled 19 charts

Breast Neoplasms

NCT01818063 2025-04-30

Carboplatin and Combination Chemotherapy With or Without Veliparib in Treating Patients With Stage IIB-IIIC Breast Cancer

Phase 2 Completed

9 enrolled 10 charts

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT00520975 2025-03-28

Bevacizumab in Treating Patients With Metastatic Breast Cancer That Overexpresses HER-2/NEU

Phase 3 Terminated

96 enrolled 16 charts

Breast Neoplasms

NCT00667251 2025-03-21

Chemotherapy and Lapatinib or Trastuzumab in Treating Women With HER2/Neu-Positive Metastatic Breast Cancer

Phase 3 Completed

652 enrolled 50 charts

Breast Neoplasms

NCT03165955 2025-03-12

A Clinical Study to Determine the Pharmacokinetics of Oraxol in Breast Cancer Patients

Phase 1 Completed

28 enrolled 20 charts

Breast Neoplasms

NCT02163694 2025-02-19

A Phase 3 Randomized, Placebo-controlled Trial of Carboplatin and Paclitaxel With or Without Veliparib (ABT-888) in HER2-negative Metastatic or Locally Advanced Unresectable BRCA-associated Breast Cancer

Phase 3 Completed

513 enrolled 16 charts

Breast Neoplasms

NCT01084876 2025-02-11

Compare

Phase 3 Completed

475 enrolled 25 charts

Breast Neoplasms

NCT01084863 2025-01-24

Compare

Phase 1/2 Completed

143 enrolled 23 charts

Breast Neoplasms

NCT04215146 2025-01-16

A Study to Assess Overall Response Rate by Inducing an Inflammatory Phenotype in Metastatic BReast cAnCEr With the Oncolytic Reovirus PeLareorEp in CombinaTion With Anti-PD-L1 Avelumab and Paclitaxel - BRACELET-1 Study

Phase 2 Active not recruiting

48 enrolled 13 charts

Breast Neoplasms

NCT04109066 2025-01-08

CheckMate 7FL

Phase 3 Completed

521 enrolled 17 charts

Breast Neoplasms, Neoplasms

NCT03601897 2024-12-27

A Phase 1b/2 Study of Rebastinib (DCC-2036) in Combination With Paclitaxel in Patients With Advanced or Metastatic Solid Tumors

Phase 1/2 Terminated

177 enrolled 25 charts

BreastGynecologicSarcoma

Breast Neoplasms, Carcinosarcoma, Neoplasm Metastasis, Ovarian Neoplasms, Endometrial Neoplasms

NCT01897441 2024-12-24

Chemotherapy Before Surgery and Tissue Sample Collection in Patients With Stage IIA-IIIC Breast Cancer

Phase NA Terminated

31 enrolled 11 charts

Breast Neoplasms

NCT03644186 2024-12-13

TOUCH

Phase 2 Completed

147 enrolled 11 charts

Breast Neoplasms

NCT02938442 2024-11-07

Vaccination of Triple Negative Breast Cancer Patients

Phase 1/2 Completed

16 enrolled 30 charts

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT03726879 2024-11-05

IMpassion050

Phase 3 Completed

454 enrolled 28 charts

Breast Neoplasms

NCT03800836 2024-10-30

A Study to Evaluate the Safety and Efficacy of Ipatasertib in Combination With Atezolizumab and Paclitaxel or Nab-Paclitaxel in Participants With Locally Advanced or Metastatic Triple-Negative Breast Cancer

Phase 1 Completed

139 enrolled 24 charts

Breast Neoplasms

NCT02187991 2024-10-09

Study to Compare Alisertib With Paclitaxel vs. Paclitaxel Alone in Metastatic or Locally Recurrent Breast Cancer

Phase 2 Completed

169 enrolled 15 charts

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT03839823 2024-10-09

RIGHT Choice

Phase 2 Completed

222 enrolled 17 charts

Breast Neoplasms